

To: European Commission, Directorate-General Health and Food Safety, Directorate C, Unit C2 - State of Health, European Semester, Health Technology Assessment ([SANTE-HTA-NETWORK@ec.europa.eu](mailto:SANTE-HTA-NETWORK@ec.europa.eu))

## SIOPE EUROPE MEMBERSHIP DECLARATION

### a) SIOPE EUROPE MEMBERSHIP

The paediatric oncology community in Europe is the foundation and driving force of the European Society for Paediatric Oncology (SIOPE Europe, or SIOPE). We currently count more than 2500 members from 35 countries in the European region. Further information on the exact membership may be accessed [here](#).

### b) SIOPE EUROPE AS A MEMBER

In order to expand outreach and scope as an organisation, SIOPE develops its activities also through affiliation with other entities. SIOPE is therefore currently a member of the following organisations / networks:

- [SIOPE](#), the International Society of Paediatric Oncology
- [ACCELERATE Platform](#)
- [EURORDIS](#), Rare Diseases Europe
- [EFGCP](#), the European Forum for Good Clinical Practice
- [Rare Cancers Europe](#)
- [TRANSFORM](#), European Alliance for Transformative Therapies
- [WHO Europe Novel Medicines Platform \(NMP\)](#)



### c) SIOPE EUROPE PARTNERSHIPS

To ensure the best possible care and outcome for all children and young people with cancer in Europe, SIOPE establishes close collaborations with several European organisations representing the point of view of paediatric cancer patients and parents, survivors ([Childhood Cancer International – Europe, CCI Europe](#)), paediatricians, adult oncology and rare disease advocates. More information can be found on [SIOPE website](#).

### d) EU TRANSPARENCY REGISTER

Importantly, [SIOPE Europe is registered in the official EU Transparency Register of interest representatives](#) (id. nr.: 122803916413-09).